[P29] Poster Session 29　Lung Cancer/Thoracic Cancer（ICI efficacy 1）

[P29-1] LIGHT-NING: An observational study of nivolumab plus ipilimumab with or without chemotherapy for 1st line NSCLC in Japan

^○Takashi Kijima¹, Koichi Azuma², Hidetoshi Hayashi³, Koichi Nakatani⁴, Tatsuro Fukuhara⁵, Yukihiro Toi⁶, Hisao Imai⁷, Yasuto Yoneshima⁸, Hideaki Mizutani⁹, Tomohiro Ozaki¹⁰, Satoru Kitazono¹¹, Naoki Ide¹², Keisuke Suzuki¹³, Hidehito Horinouchi¹⁴, Yuichiro Ohe¹⁴ (1.Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Hyogo, Japan, 2.Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University, School of Medicine, Fukuoka, Japan, 3.Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan, 4.Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan, 5.Department of Respiratory Medicine, Miyagi Cancer Center, Miyagi, Japan, 6.Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan, 7.Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan, 8.Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 9.Department of Thoracic Oncology, Saitama Prefectural Cancer Center, Saitama, Japan, 10.Department of Medical Oncology, Kishiwada City Hospital, Osaka, Japan, 11.Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, 12.Bristol-Myers Squibb K.K., Japan, 13.Ono Pharmaceutical Co., Ltd., Japan, 14.Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan)